Lumos Pharma, Inc. (LUMO): Price and Financial Metrics
Lumos Pharma, Inc. (LUMO)
Today's Latest Price: $18.47 USD
Updated Jan 26 4:00pm
Add LUMO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
LUMO Stock Summary
- The ratio of debt to operating expenses for Lumos Pharma Inc is higher than it is for about just 5.54% of US stocks.
- With a price/sales ratio of 284.85, Lumos Pharma Inc has a higher such ratio than 98.11% of stocks in our set.
- With a year-over-year growth in debt of -71.31%, Lumos Pharma Inc's debt growth rate surpasses only 3.66% of about US stocks.
- Stocks that are quantitatively similar to LUMO, based on their financial statements, market capitalization, and price volatility, are OPTT, LCTX, AIM, EDSA, and SWAV.
- LUMO's SEC filings can be seen here. And to visit Lumos Pharma Inc's official web site, go to www.lumos-pharma.com.
LUMO Stock Price Chart Interactive Chart >
LUMO Price/Volume Stats
| Current price | $18.47 | 52-week high | $36.72 |
| Prev. close | $19.26 | 52-week low | $6.74 |
| Day low | $17.60 | Volume | 41,357 |
| Day high | $19.50 | Avg. volume | 54,544 |
| 50-day MA | $20.47 | Dividend yield | N/A |
| 200-day MA | $15.50 | Market Cap | 153.25M |
Lumos Pharma, Inc. (LUMO) Company Bio
Lumos Pharma, Inc. operates as a biopharmaceutical company. The Company discovers, develops, and commercializes therapeutics for patients and families living with rare diseases. Lumos Pharma operates worldwide.
LUMO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $18.47 | $0.68 | -96% |
Below please find a table outlining a discounted cash flow forecast for LUMO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Lumos Pharma Inc ranked in the 7th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 96.33%. In terms of the factors that were most noteworthy in this DCF analysis for LUMO, they are:
- The company's compound free cash flow growth rate over the past 5.51 years comes in at -0.37%; that's greater than only 3.96% of US stocks we're applying DCF forecasting to.
- Relative to other stocks in its sector (Healthcare), Lumos Pharma Inc has a reliance on debt greater than just 6.67% of them.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -97% |
| 1% | -97% |
| 2% | -96% |
| 3% | -96% |
| 4% | -96% |
| 5% | -96% |
INFU, NVST, PHG, PPD, and SXTC can be thought of as valuation peers to LUMO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...